Literature DB >> 21349111

Comparison of the clinical efficacy of NBUVB and NBUVB with benzoyl peroxide/clindamycin in progressive macular hypomelanosis.

J H Sim1, D J Lee, J S Lee, Y C Kim.   

Abstract

BACKGROUND: Progressive macular hypomelanosis (PMH) is a skin disorder characterized by multiple hypopigmented patches symmetrically distributed on the trunk. Several treatment modalities have been attempted; however, a standard treatment modality has not been agreed to.
OBJECTIVES: The aim of this study was to compare the effectiveness of antimicrobial therapy combined with narrow band ultraviolet B (NBUVB) with NBUVB monotherapy.
METHODS: A randomized left-right comparison study was conducted in a total of 10 patients. Patients received NBUVB therapy with daily application of antimicrobial gel on one side of the trunk (comb-NBUVB) and without it (mono-NBUVB) for 8 weeks. The clinical efficacy was determined by objective measurements using a colour analyser and subjective assessment by evaluating pictures taken with a digital camera at baseline, at the time of treatment cessation and 6 months after treatment.
RESULTS: Significant repigmentation was observed in all 10 patients during the 8 weeks of treatment. The mean difference in L values between lesional and non-lesional skin was reduced in the comb-NBUVB area (from 4.52 ± 1.65 to 0.94 ± 0.65), and in the mono-NBUVB area, (from 4.34 ± 1.39 to 1.18 ± 0.94). There was no significant difference between treated sites at both of the evaluation points in time. At 6 months after treatment, 7 of 10 patients completed the clinical trial, and some degree of clinical improvement remained in four of seven patients; recurrence occurred in the other patients.
CONCLUSIONS: Although recurrence occurred in some patients, NBUVB treatment appears to be a safe and useful modality for the treatment of PMH.
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349111     DOI: 10.1111/j.1468-3083.2011.03980.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  2 in total

1.  Propionibacterium Acnes Phylogenetic Type III is Associated with Progressive Macular Hypomelanosis.

Authors:  Rolf L W Petersen; Christian F P Scholz; Anders Jensen; Holger Brüggemann; Hans B Lomholt
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-02-27

2.  Adjuvant Narrow Band UVB Improves the Efficacy of Oral Azithromycin for the Treatment of Moderate to Severe Inflammatory Facial Acne Vulgaris.

Authors:  Sima Rassai; Esmaeil Rafeie; Marigdalia K Ramirez-Fort; Amir Feily
Journal:  J Cutan Aesthet Surg       Date:  2014-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.